Guggenheim Bullish on Oruka Therapeutics with $60 Target
Guggenheim starts coverage of Oruka Therapeutics with Buy rating and $60 target, praising its longer-acting antibody drugs for chronic inflammation treatment.
/ 921 items
#Healthcare↓
Wells Fargo Upgrades Glaukos: Hidden Growth Driver Spotted
Wells Fargo raises Glaukos price target to $120, citing Epioxa as underappreciated growth catalyst beyond iDose focus. Stock upgrade to Overweight.
Novartis Makes Bold $12 Billion Move with Avidity Biosciences Acquisition in Largest Deal Under CEO Narasimhan
Novartis acquires Avidity Biosciences for $12 billion, gaining access to breakthrough RNA therapeutics for neuromuscular diseases as the Swiss drugmaker prepares for upcoming patent expirations on key drugs.
BofA Boosts Doximity Rating as Drug Ad Strategy Changes
Bank of America raises Doximity to Buy with $82 target as pharma companies redirect ad spending from consumers to doctors amid new FDA regulations.
FDA Approves Revuforj for Relapsed NPM1 Mutated Acute Myeloid Leukemia
FDA has approved Revuforj (revumenib) for use in adult and pediatric patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. However, the agency has warned of serious and potentially fatal side effects, including differentiation syndrome.
H.C. Wainwright Rates Zymeworks a Buy on Promising ZW191 Cancer Drug Data
H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.